Log in to your Inderes Free account to see all free content on this page.

Mentice

14

SEK

-3.11 %

Less than 1K followers

MNTC

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

-3.11%

-28.75%

-26.32%

-43.32%

-45.1%

-48.53%

-82.05%

-81.06%

-79.29%

Mentice is a medical technology company. The company develops medical instruments for endovascular simulation and for training sessions in surgery. The programs are developed for educational use in hospitals and institutes. The largest operations are established in North America and Europe. In addition to the main business, the company also offers leasing, support, and technical service. The head office is located in Gothenburg.

Market cap

357.96M SEK

Turnover

33.37K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

24.7.

2025

Interim report Q2'25

6.11.

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Press releaseyesterday

Mentice AB Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service Delivery

Press release7/10/2025, 6:00 AM

Mentice to Present Q2 2025 Interim Report via Webcast

Press release6/18/2025, 11:00 AM

BioStock: Mentice announces workforce realignment and plans capital raise

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release6/18/2025, 8:45 AM

DNB Carnegie Access: Mentice: Cost-cutting programme highlights short-term challenges

Regulatory press release6/16/2025, 1:58 PM

Mentice AB announces the intent for a strategic workforce realignment to enhance focus and operational efficiency and the intent for a rights issue of max 10% of the share capital

Regulatory press release5/27/2025, 2:00 PM

Communique from annual general meeting in Mentice AB

Press release5/23/2025, 12:47 PM

DNB Carnegie Access: Mentice: Secures USD0.64m order – Quick comment

Regulatory press release5/23/2025, 9:10 AM

Mentice Secures $642,000 Order from a Top 20 Global MedTech Company in Interventional Cardiology

Press release5/13/2025, 1:23 PM

DNB Carnegie Access: Mentice: FDA 510(k) clearance for latest version of Ankyras software

Press release5/13/2025, 11:00 AM

Mentice Launch the latest version of Ankyras® in the United States Following FDA Clearance, Advancing Patient-Specific Aneurysm Planning for Neuro interventions

Press release5/9/2025, 6:28 AM

Mentice AB: Mentice's CEO to BioStock: "We anticipate a further ramp up in our sales"

Press release5/9/2025, 5:37 AM

Carnegie Access: Mentice: Facing FX headwinds and a challenging market – Q1 review

Press release5/8/2025, 9:00 AM

Carnegie Access: Mentice: Recording from Earnings Call Q1(25)

Press release5/8/2025, 8:12 AM

Carnegie Access: Mentice: Sales growth in line with long-term targets – Q1 quick comment

Regulatory press release5/8/2025, 6:30 AM

Mentice publishes the company’s interim report for the period January–March 2025

Press release5/7/2025, 8:33 AM

Mentice AB: BioStock: Mentice launches Ankyras in Brazil

Press release5/5/2025, 12:35 PM

Mentice Expands Ankyras® to Brazil Following Successful ANVISA Notification, Bringing Advanced Intracranial Aneurysm Treatment Planning to Latin America

Press release4/30/2025, 8:00 AM

Mentice to Present Q1 2025 Interim Report via Webcast

Regulatory press release4/17/2025, 6:30 AM

Mentice AB Publishes Annual and Sustainability Report for 2024 – Strong finish to 2024 following a transitional year

Regulatory press release4/16/2025, 6:30 PM

Annual shareholders’ meeting in Mentice AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.